Massachusetts Financial Services Co. MA Cuts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Massachusetts Financial Services Co. MA lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 28,379 shares of the medical equipment provider’s stock after selling 1,500 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Hologic were worth $2,107,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in HOLX. PNC Financial Services Group Inc. lifted its holdings in Hologic by 0.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 31,933 shares of the medical equipment provider’s stock worth $2,282,000 after buying an additional 288 shares during the last quarter. Coldstream Capital Management Inc. acquired a new position in Hologic in the fourth quarter valued at approximately $305,000. D.A. Davidson & CO. purchased a new position in Hologic in the fourth quarter valued at approximately $204,000. Corient Private Wealth LLC raised its holdings in Hologic by 251.1% during the fourth quarter. Corient Private Wealth LLC now owns 51,106 shares of the medical equipment provider’s stock worth $3,652,000 after purchasing an additional 36,550 shares in the last quarter. Finally, SageView Advisory Group LLC purchased a new stake in shares of Hologic during the 4th quarter worth approximately $289,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Christiana Stamoulis sold 9,039 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now owns 45,472 shares in the company, valued at approximately $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the transaction, the director now directly owns 45,472 shares of the company’s stock, valued at approximately $3,615,024. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Stephen P. Macmillan sold 3,672 shares of the company’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at approximately $92,755,443.06. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Tuesday, September 17th. JPMorgan Chase & Co. lifted their target price on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Royal Bank of Canada reissued a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 18th. Finally, Stephens reissued an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.60.

Hologic Trading Down 1.2 %

Shares of Hologic stock opened at $81.39 on Monday. The firm has a market cap of $18.99 billion, a price-to-earnings ratio of 41.53, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $84.67. The company’s 50-day simple moving average is $80.82 and its 200-day simple moving average is $77.13. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same period in the prior year, the business posted $0.93 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.09 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.